The purpose of this study is to see if safe and effective device therapy can be provided and reduce inappropriate therapy. Currently the subject would be offered devices programmed for those who have had a cardiac arrest.
Primary prevention patient with ischemic or non-ischemic heart disease who meets current guideline for dual-chamber ICD or CRT-D device therapy.
Patient in sinus rhythm.
Patient on stable optimal pharmacologic therapy for the cardiac condition or who has developed a recent ICD indication that necessitates ICD therapy concurrent with the optimization of pharmacologic therapy.
Patient = 21 years of age, or legal representative, willing and capable of giving informed consent.
Patient must be able to read, write, and speak English.
Patient with an implanted pacemaker or CRT-P.
Patient with existing ICD or CRT-D device components.
Patient with a history of spontaneous sustained VT or VF (> 160 beats/minute).
Patient with permanent or chronic AF, or cardioversion for AF, within the past three calendar months before enrollment.
Patient with coronary artery bypass graft surgery or percutaneous coronary intervention within the past three calendar months prior to enrollment.
Patient with enzyme-positive myocardial infarction within the past three calendar months prior to enrollment.
Patient with angiographic evidence of coronary disease who are candidates for coronary revascularization and are likely to undergo coronary artery bypass graft surgery or, percutaneous coronary intervention in the foreseeable future.
Patient with second or third degree heart block.
Patient in NYHA Class IV.
Patient who is pregnant or plans to become pregnant during the course of the trial.
Patient with irreversible brain damage from preexisting cerebral disease
Patient with presence of any disease, other than the patient’s cardiac disease, associated with a reduced likelihood of survival for the duration of the trial, e.g., cancer, uremia,liver failure, etc.
Patient with chronic renal disease with BUN = 50mg/dl or creatinine = 2.5 mg/dl.